My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our clinical teams ...

Over to you, Bob. Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our ...

Amgen's revenue has gained yearly from 2015 to 2024, except for slight declines in 2017 and 2019. Amgen is growing organically because of its own R&D and pipeline. The firm has a strong presence ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...

In 2024, when Amgen generated $33.4 billion in revenue, more than $2.2 billion came from sales of its biosimilars. It was a 16% increase from Amgen’s biosimilar sales in 2023 and the company ...

Dividend: $2.25 per share in the fourth quarter, a 6% increase from 2023. Amgen Inc (NASDAQ:AMGN) reported a 19% year-over-year increase in total revenues for 2024, driven by strong product sales ...

The 90th edition of the WM Phoenix Open boasted larger spaces, multiple points of entry and new ticket regulations.

THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.